Skip to content

VEDA Study (DHEA vs Estradiol)

The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07574216
Enrollment
324
Registered
2026-05-07
Start date
2026-06-01
Completion date
2031-12-31
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause, Painful Intercourse, Post-menopause, Pre-menopause, Sexual Function, Vaginal Dryness

Keywords

DHEA, vaginal estrogen

Brief summary

This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.

Detailed description

This research study is being conducted to compare two commonly used vaginal therapies vaginal estrogen and vaginal DHEA for the treatment of vaginal and urinary symptoms that occur after menopause. Many postmenopausal women experience symptoms such as vaginal dryness, irritation, painful intercourse, decreased sexual comfort, or urinary symptoms including burning, urgency, or recurrent urinary discomfort. These symptoms, often related to decreased estrogen levels, can significantly affect daily activities, intimate relationships, and overall quality of life. In this study, women who choose to participate will be randomly assigned (like the flip of a coin) to use either vaginal estrogen or vaginal DHEA for a defined treatment period. Randomization ensures that each participant has an equal chance of receiving either treatment, which helps researchers make fair and unbiased comparisons between the two options. Participants will complete questionnaires at several time points throughout the study to report on their symptoms, sexual health, comfort, and overall satisfaction with treatment. At the beginning and end of the study, participants will also undergo simple vaginal assessments, which may include vaginal pH testing, collection of vaginal swabs, or other non-invasive measurements to evaluate changes in vaginal health over time. The goal of this research is to gain a deeper understanding of how each treatment affects vaginal tissue health, sexual function, urinary symptoms, and overall well-being. By comparing these two therapies directly, the study aims to provide healthcare providers with clearer evidence about which treatment may be more effective for specific symptoms or patient needs. Ultimately, the findings may help improve clinical care and offer women more tailored, evidence-based options for managing postmenopausal vaginal and urinary symptoms.

Interventions

DRUGDHEA ovals

DHEA (dehydroepiandrosterone) is an inactive hormone precursor naturally produced by the body. When placed locally in the vagina, it is converted by vaginal cells into small amounts of estrogen and androgens exactly where the tissues need them. This helps restore the vaginal lining, improve moisture, and reduce pain.

Estradiol 0.01% vaginal cream is a local (vaginal) estrogen therapy used to treat symptoms of genitourinary syndrome of menopause (GSM)-the thinning, dryness, and inflammation of vaginal and urinary tissues caused by postmenopausal estrogen decline.

Sponsors

University of Arizona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Peri- or post-menopausal status * Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia) * Willingness and ability to use vaginal therapy * Ability to provide informed consent * English speaker * Ages 40-90

Exclusion criteria

* Use of systemic hormone therapy within the last 6 months * Gynecologic malignancy * Known allergy to study medications * Active vaginal infection at enrollment * Prior pelvic radiation

Design outcomes

Primary

MeasureTime frameDescription
Genitourinary SymptomsBaseline/post treatment (6 month follow up)To compare the change in FSFI scores from baseline visit to post-treatment visit with vaginal DHEA versus vaginal estrogen among postmenopausal women with genitourinary symptoms.

Secondary

MeasureTime frameDescription
Recurrent urinary tract infectionsBaseline/post treatment (6 month follow up)To compare changes from baseline-visit to post-treatment visit in: vaginal pH and recurrent urinary tract infections before and after treatment with vaginal DHEA vs Vaginal estrogen. Data will show if vaginal pH is greater than 4.5 indicating a UTI.

Contacts

CONTACTIridian (Iris) Jaramillo, M.S.
iyjaramillo@arizona.edu602-827-2078
CONTACTPamela C Garcia-Filion, MD
pgarciafilion@arizona.edu602-827-2882
PRINCIPAL_INVESTIGATORMolloy Shaida

University of Arizona

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026